Single-cell phenotypes of peripheral blood immune cells in early and late stages of non-alcoholic fatty liver disease
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: Immune and inflammatory cells respond to multiple pathological hits in the development of nonalcoholic steatohepatitis (NASH) and fibrosis. Relatively little is known about how their type and function change through the non-alcoholic fatty liver disease (NAFLD) spectrum. Here we used multi-dimensional mass cytometry and a tailored bioinformatic approach to study circulating immune cells sampled from healthy individuals and people with NAFLD. Methods: Cytometry by time of flight using 36 metal-conjugated antibodies was applied to peripheral blood mononuclear cells (PBMCs) from biopsy-proven NASH fibrosis (late disease), steatosis (early disease), and healthy patients. Supervised and unsupervised analyses were used, findings confirmed, and mechanisms assessed using independent healthy and disease PBMC samples. Results: Of 36 PBMC clusters, 21 changed between controls and disease samples. Significant differences were observed between diseases stages with changes in T cells and myeloid cells throughout disease and B cell changes in late stages. Semi-supervised gating and re-clustering showed that disease stages were associated with fewer monocytes with active signalling and more inactive NK cells; B and T cells bearing activation markers were reduced in late stages, while B cells bearing co-stimulatory molecules were increased. Functionally, disease states were associated with fewer activated mucosal-associated invariant T cells and reduced toll-like receptor-mediated cytokine production in late disease. Conclusions: A range of innate and adaptive immune changes begin early in NAFLD, and disease stages are associated with a functionally less active phenotype compared to controls. Further study of the immune response in NAFLD spectrum may give insight into mechanisms of disease with potential clinical application.
Abstract
Background/Aims: Immune and inflammatory cells respond to multiple pathological hits in the development of nonalcoholic steatohepatitis (NASH) and fibrosis. Relatively little is known about how their type and function change through the non-alcoholic fatty liver disease (NAFLD) spectrum. Here we used multi-dimensional mass cytometry and a tailored bioinformatic approach to study circulating immune cells sampled from healthy individuals and people with NAFLD. Methods: Cytometry by time of flight using 36 metal-conjugated antibodies was applied to peripheral blood mononuclear cells (PBMCs) from biopsy-proven NASH fibrosis (late disease), steatosis (early disease), and healthy patients. Supervised and unsupervised analyses were used, findings confirmed, and mechanisms assessed using independent healthy and disease PBMC samples. Results: Of 36 PBMC clusters, 21 changed between controls and disease samples. Significant differences were observed between diseases stages with changes in T cells and myeloid cells throughout disease and B cell changes in late stages. Semi-supervised gating and re-clustering showed that disease stages were associated with fewer monocytes with active signalling and more inactive NK cells; B and T cells bearing activation markers were reduced in late stages, while B cells bearing co-stimulatory molecules were increased. Functionally, disease states were associated with fewer activated mucosal-associated invariant T cells and reduced toll-like receptor-mediated cytokine production in late disease. Conclusions: A range of innate and adaptive immune changes begin early in NAFLD, and disease stages are associated with a functionally less active phenotype compared to controls. Further study of the immune response in NAFLD spectrum may give insight into mechanisms of disease with potential clinical application.
참고문헌 (45)
- Paik JM, "Global burden of NAFLD and chronic liver disease among adolescents and young adults", Hepatology, 75, pp.1204~1217 (2022)
- Ekstedt M, "Fibrosis stage is the strongest predictor for diseasespecific mortality in NAFLD after up to 33 years of follow-up", Hepatology, 61, pp.1547~1554 (2015)
- Dulai PS, "Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease : Systematic review and meta-analysis", Hepatology, 65, pp.1557~1565 (2017)
- Lin SZ, "Peripheral immune cells in NAFLD patients : a spyhole to disease progression", EBioMedicine, 75, pp.103768~ (2022)
- Lambrecht J, "Controversies and opportunities in the use of inflammatory markers for diagnosis or risk prediction in fatty liver disease", Front Immunol, 11, pp.634409~ (2021)
- Friedman SL, "Mechanisms of NAFLD development and therapeutic strategies", Nat Med, 24, pp.908~922 (2018)
- Inzaugarat ME, "Altered phenotype and functionality of circulating immune cells characterize adult patients with nonalcoholic steatohepatitis", J Clin Immunol, 31, pp.1120~1130 (2011)
- Rau M, "Progression from nonalcoholic fatty liver to nonalcoholic steatohepatitis is marked by a higher frequency of Th17 cells in the liver and an increased Th17", resting regulatory T cell ratio in peripheral blood and in the liver, 2016, pp.196, 97~105
- Deng T, "Class II major histocompatibility complex plays an essential role in obesityinduced adipose inflammation", Cell Metab, 17, pp.411~422 (2013)
- Stiglund N, "Retained NK cell phenotype and functionality in nonalcoholic fatty liver disease", Front Immunol, 10, pp.1255~ (2019)
- Wang Y, "A nonclassical monocyte phenotype in peripheral blood is associated with nonalcoholic fatty liver disease : a report from an EMIL subcohort", Horm Metab Res, 48, pp.54~61 (2016)
- Gadd VL, "Altered peripheral blood monocyte phenotype and function in chronic liver disease : implications for hepatic recruitment and systemic inflammation", PLoS One, 11, pp.e0157771~ (2016)
- Zhang J, "Increased intermediate monocyte fraction in peripheral blood is associated with nonalcoholic fatty liver disease", Wien Klin Wochenschr, 130, pp.390~397 (2018)
- McPherson S, "Serum immunoglobulin levels predict fibrosis in patients with nonalcoholic fatty liver disease", J Hepatol, 60, pp.1055~1062 (2014)
- Kleiner DE, "Design and validation of a histological scoring system for nonalcoholic fatty liver disease", Hepatology, 41, pp.1313~1321 (2005)
- Kotecha N, "Web-based analysis and publication of flow cytometry experiments", Curr Protoc Cytom, 53(Suppl), pp.10.17.1~10.17.24 (2010)
- "Robust integration of single-cell cytometry datasets" (2021)[URL]
- McInnes L, "UMAP : uniform manifold approximation and projection", J Open Source Softw, 3, pp.861~ (2018)
- Stassen SV, "PARC : ultrafast and accurate clustering of phenotypic data of millions ofsingle cells", Bioinformatics, 36, pp.2778~2786 (2020)
- Weber LM, "Diffcyt : differential discovery in high-dimensional cytometry via highresolution clustering", Commun Biol, 2, pp.183~ (2019)
- Benjamini Y, "Controlling the false discovery rate : a practical and powerful approach to multiple testing", J R Stat Soc Series B Stat Methodol, 57, pp.289~300 (1995)
- "Liver Cell Atlas"[URL]
- Sutti S, "Adaptive immunity : an emerging player in the progression of NAFLD", Nat Rev Gastroenterol Hepatol, 17, pp.81~92 (2020)
- Dudek M, "Auto-aggressive CXCR6+ CD8 T cells cause liver immune pathology in NASH", Nature, 592, pp.444~449 (2021)
- Haas JT, "Transcriptional network analysis implicates altered hepatic immune function in NASH development and resolution", Nat Metab, 1, pp.604~614 (2019)
- Albano E, "Immune response towards lipid peroxidation products as a predictor of progression of non-alcoholic fatty liver disease to advanced fibrosis", Gut, 54, pp.987~993 (2005)
- MacLeod H, "T cell activation by TLRs : a role for TLRs in the adaptive immune response", Sci STKE, 2007, pp.pe48~ (2007)
- Bruzzì S, "B2-Lymphocyte responses to oxidative stress-derived antigens contribute to the evolution of nonalcoholic fatty liver disease(NAFLD)", Free Radic Biol Med, 124, pp.249~259 (2018)
- Thapa M, "Liver fibrosis occurs through dysregulation of MyD88-dependent innate B-cell activity", Hepatology, 61, pp.2067~2079 (2015)
- Crocker PR, "Siglecs and their roles in the immune system", Nat Rev Immunol, 7, pp.255~266 (2007)
- Ekşioglu-Demiralp E, "Phenotypic characteristics of B cells in Behçet’s disease : increased activity in B cell subsets", J Rheumatol, 26, pp.826~832 (1999)
- Treiner E, "Selection of evolutionarily conserved mucosal-associated invariant T cells by MR1", Nature, 422, pp.164~169 (2003)
- Li Y, "Mucosalassociated invariant T cells improve nonalcoholic fatty liver disease through regulating macrophage polarization", Front Immunol, 9, pp.1994~ (2018)
- Hegde P, "Mucosal-associated invariant T cells are a profibrogenic immune cell population in the liver", Nat Commun, 9, pp.2146~ (2018)
- Magalhaes I, "Mucosal-associated invariant T cell alterations in obese and type 2 diabetic patients", J Clin Invest, 125, pp.1752~1762 (2015)
- Sakamoto Y, "Increased frequency of dysfunctional siglec-7-CD57+PD-1+natural killer cells in patients with non-alcoholic fatty liver disease", Front Immunol, 12, pp.603133~ (2021)
- Diedrich T, "Characterization of the immune cell landscape of patients with NAFLD", PLoS One, 15, pp.e0230307~ (2020)
- Amer J, "Insulin signaling as a potential natural killer cell checkpoint in fatty liver disease", Hepatol Commun, 2, pp.285~298 (2018)
- O’Brien KL, "Immunometabolism and natural killer cell responses", Nat Rev Immunol, 19, pp.282~290 (2019)
- Martínez-Chantar ML, "Revisiting the role of natural killer cells in non-alcoholic fatty liver disease", Front Immunol, 12, pp.640869~ (2021)
- Schuch A, "The role of natural killer cells and CD8+ T cells in hepatitis B virus infection", Front Immunol, 5, pp.258~ (2014)
- Rehermann B, "Natural killer cells in viral hepatitis", Cell Mol Gastroenterol Hepatol, 1, pp.578~588 (2015)
- Ramachandran P, "Resolving the fibrotic niche of human liver cirrhosis atsingle-cell level", Nature, 575, pp.512~518 (2019)
- Arias-Loste MT, "Increased expression profile and functionality of TLR6 in peripheral blood mononuclear cells and hepatocytes of morbidly obese patients with non-alcoholic fatty liver disease", Int J Mol Sci, 17, pp.1878~ (2016)
- Zwolak A, "Metformin changes the relationship between blood monocyte toll-like receptor 4 levels and nonalcoholic fatty liver disease-ex vivo studies", PLoS One, 11, pp.e0150233~ (2016)